NEW YORK (360Dx) – Saluggia, Italy-based DiaSorin said Thursday that it has received clearance from the US Food and Drug Administration to market the Liaison BRAHMS PCT II Gen assay for the quantitative determination of procalcitonin.

John Walter, president of DiaSorin, said in a statement that the assay is an addition to its "growing specialty menu in the US market" and that the FDA also cleared procalcitonin controls and calibration verifiers for use on its Liaison family of instruments.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.